Avandia Safety Rhetoric Ramps Up Ahead Of Advisory Committee Review

Participants in the ongoing safety debate over GlaxoSmithKline's Avandia (rosiglitazone) are refining their arguments ahead of the July 13-14 joint FDA advisory committee meeting on the troubled thiazolidinedione's future